This site is intended for health professionals only

At the heart of general practice since 1960

GPs are warned over epilepsy prescribing

Pharmaceutical company Wyeth exaggerated the benefits of Efexor (venlafaxine), regulatory authorities have ruled. A Medicines and Healthcare Products Regulatory Agency investigation found 'insufficient data' to prove Efexor offered better symptomatic relief and remission rates than SSRIs fluvoxamine and paroxetine, as Wyeth had claimed.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say